They are not selecting patients which fit the particular genetic profile for best efficacy. The ph2b/3 will be confirming genetic findings from the ph2a
Remember AVXL is recruiting using precision medicine and screening patients as much as possible for the specific biomarkers that were found after years of genetic testing on first patient population in Aussie land
Hmm, I thought Anavex was not selecting using precision medicine biomarkers. I think you're wrong